Stockscreener 앱 받기
19.19
1.59%
-0.31
시간 외 거래:
19.08
-0.11
-0.57%
전일 마감가:
$19.50
열려 있는:
$19.15
하루 거래량:
191.43K
Relative Volume:
1.17
시가총액:
$297.25M
수익:
$925.00K
순이익/손실:
$-85.13M
주가수익비율:
-4.3341
EPS:
-4.4277
순현금흐름:
$-78.10M
1주 성능:
-13.95%
1개월 성능:
+3.06%
6개월 성능:
+11.57%
1년 성능:
+24.45%
1일 변동 폭
$18.23
$19.42
1주일 범위
$18.23
$22.32
52주 변동 폭
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
명칭
Neurogene Inc
전화
(877) 237-5020
주소
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
19.19 | 302.05M | 925.00K | -85.13M | -78.10M | -4.4277 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Craig Hallum | Buy |
| 2025-05-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2024-03-21 | 개시 | William Blair | Outperform |
| 2024-01-08 | 개시 | H.C. Wainwright | Buy |
| 2024-01-05 | 개시 | Stifel | Buy |
| 2024-01-04 | 개시 | TD Cowen | Outperform |
모두보기
Neurogene Inc 주식(NGNE)의 최신 뉴스
Neurogene Inc: chief scientific officer Cobb sells $141k in stock - Investing.com
Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 4,045 Shares of Stock - MarketBeat
Neurogene (NGNE) CSO sells 6,797 shares under 10b5-1 plan - Stock Titan
Tax-driven share sale by Neurogene (NGNE) president and CFO disclosed - Stock Titan
Published on: 2026-03-17 03:31:12 - baoquankhu1.vn
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
[144] Neurogene Inc. SEC Filing - Stock Titan
Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Bluefield Daily Telegraph
Genetic-medicine firm Neurogene in Stifel 2026 virtual CNS fireside chat - Stock Titan
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
NGNE: Durable functional gains in Rett syndrome drive NGN-401's pivotal trial and commercial plans - TradingView
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, with pivotal data expected mid-2024 - TradingView
Gains Recap: Whats the analyst consensus on Neurogene Inc2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Will Neurogene Inc. stock outperform value stocksInsider Buying & Accurate Buy Signal Alerts - Naître et grandir
Aug Update: How correlated is Neurogene Inc to the S P500Chart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Layoff Watch: Is Neurogene Inc part of any major indexJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Aug Movers: Is Neurogene Inc backed by strong institutional buyingJuly 2025 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Macro Review: Is Neurogene Inc in a long term uptrend2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan - Stock Titan
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Analysts Are Bullish on Top Healthcare Stocks: Mesoblast Limited (MEOBF), Neurogene (NGNE) - The Globe and Mail
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
Should You Buy Neurogene Inc (NGNE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Neurogene: Stock Soars On FDA Designation For Rett Gene TherapyI'd Remain Cautious - Seeking Alpha
Canaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - Nasdaq
Neurogene (NASDAQ:NGNE) Now Covered by Canaccord Genuity Group - MarketBeat
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
FDA grants breakthrough therapy status to Neurogene’s Rett drug - Investing.com India
Why Is Neurogene Stock Skyrocketing Friday?Neurogene (NASDAQ:NGNE) - Benzinga
Neurogene : NGNE - 24/7 Wall St.
Neurogene Inc (ticker: NGNE) shares surged 32% in pre-market trading after the company announced that its experimental therapy for rare neurological diseases has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (F - Bitget
Neurogene Gets FDA Breakthrough Tag For NGN-401 In Rett Syndrome; Stock Up - Nasdaq
FDA grants breakthrough therapy status to Neurogene’s Rett drug By Investing.com - Investing.com Australia
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy - TipRanks
Neurogene stock surges 30% on FDA breakthrough therapy status - Investing.com
Neurogene stock surges 30% on FDA breakthrough therapy status By Investing.com - Investing.com Australia
Neurogene Inc. wins FDA Breakthrough Therapy Designation for NGN-401 gene therapy - Traders Union
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy - Bitget
Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome - marketscreener.com
FDA grants Breakthrough status to Neurogene (NGNE) Rett gene therapy - Stock Titan
FDA fast-tracks one-time Rett syndrome gene therapy from Neurogene - Stock Titan
Neurogene Inc. (NGNE) Stock Analysis: Exploring a Potential 184.72% Upside in the Biotech Sector - DirectorsTalk Interviews
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome - Weekly Voice
NGNE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Neurogene Inc. (NGNE) CSO awarded 16,500 restricted stock units - Stock Titan
Neurogene (NGNE) CMO receives new stock option and RSU grants - Stock Titan
[Form 4] Neurogene Inc. Insider Trading Activity - Stock Titan
Neurogene (NGNE) grants 12,050 non-qualified stock options to director Palekar - Stock Titan
Neurogene Inc (NGNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):